AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
Systematic review of intrathecal therapy for leptomeningeal metastasis in non-small cell lung cancer
Intrathecal therapy may help some lung cancer patients with brain lining spread
This systematic review evaluates intrathecal therapy for adult patients with NSCLC-related leptomeningeal metastasis using ten original stud…
A review of ten studies suggests intrathecal therapy can improve symptoms and clear cancer cells from spinal fluid for some lung cancer pati…
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Narrative review of treatment strategies for primary central nervous system lymphoma
A Smarter Way to Treat a Rare Brain Lymphoma Is Emerging
This narrative review covers treatment strategies for primary central nervous system lymphoma, including HD-MTX-based regimens, HDC-ASCT, an…
A rare lymphoma hiding in the brain now has sharper risk tools and smarter drug combos that could mean fewer relapses and less toxic treatme…
CPX-351 improves survival in AML with myelodysplasia-related changes
New leukemia treatment works best for specific gene type
This randomized phase 3 trial in 184 patients with AML and myelodysplasia-related mutations evaluated CPX-351 versus standard cytarabine plu…
A leukemia drug thought to help many patients actually works only in those with a specific genetic subtype, leaving others in need of better…
Case report describes myeloid sarcoma relapse in breast after nasal cavity presentation
A rare cancer returns to the breast six years after nasal treatment
This case report details the clinical course of a 68-year-old female with myeloid sarcoma and acute myeloid leukemia.
A rare blood cancer can hide in the breast for years and look exactly like a normal tumor without special lab tests
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Phase 1 trial of off-the-shelf NK cell therapy shows no DLTs or responses in relapsed/refractory AML
A Safer, Ready-to-Use Cell Therapy Takes Aim at Tough Leukemia
A single-arm, open-label, dose-escalation Phase 1 trial enrolled 6 adults with relapsed/refractory AML who received SAR445419, an off-the-sh…
A new, ready-to-use cell therapy proved safe in a first human trial for aggressive leukemia, offering hope for patients who have run out of …
Dasatinib Added to Intensive Chemotherapy Fails to Improve Survival in CBF-AML
Adding Dasatinib to Chemo Does Not Help CBF-AML Patients
A phase 3 randomized trial in 202 adults with core-binding factor acute myeloid leukemia (CBF-AML) found adding dasatinib to intensive chemo…
Adding dasatinib to standard chemotherapy did not improve survival for adults with core-binding factor acute myeloid leukemia and increased …